Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 24,765 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 24,765 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of the sale, the chief financial officer owned 60,753 shares in the company, valued at approximately $6,332,892.72. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Asif Ali also recently made the following trade(s):

• On Tuesday, January 27th, Asif Ali sold 46,203 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39.
• On Tuesday, January 20th, Asif Ali sold 8,588 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $82.48, for a total value of $708,338.24.

Protagonist Therapeutics Stock Down 3.1%

NASDAQ PTGX opened at $98.97 on Friday. The company has a market cap of $6.32 billion, a price-to-earnings ratio of -48.28 and a beta of 2.23. Protagonist Therapeutics, Inc. has a twelve month low of $39.60 and a twelve month high of $105.69. The business’s fifty day moving average is $88.99 and its 200 day moving average is $82.50.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The firm had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Institutional Trading of Protagonist Therapeutics

Large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after purchasing an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after acquiring an additional 348 shares during the last quarter. Millennium Management LLC grew its stake in shares of Protagonist Therapeutics by 283.6% in the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after acquiring an additional 99,269 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Protagonist Therapeutics by 21.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,414 shares of the company’s stock worth $133,000 after acquiring an additional 422 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its position in Protagonist Therapeutics by 18.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 17,000 shares of the company’s stock worth $940,000 after purchasing an additional 2,600 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Key Stories Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: One‑year Phase 3 clinical data for ICOTYDE (icotrokinra) were presented at the 2026 AAD meeting showing durable skin clearance and a favorable safety profile for this once‑daily oral IL‑23 receptor targeted peptide, reinforcing ICOTYDE’s differentiated positioning in moderate‑to‑severe plaque psoriasis. AAD Presentation
• Positive Sentiment: An analyst price target was raised (reported as an 11.65% increase to $114.50), which signals at least one analyst firm sees more upside following recent data/updates. Analyst optimism can support longer‑term upside. Price Target Increase
• Neutral Sentiment: Industry/strategy commentary (ClearBridge / ClearBridge Small Cap Growth Strategy mention) discusses the company’s pipeline and potential; useful context but not an immediate catalyst. Industry Note
• Negative Sentiment: Multiple insiders (including the CFO Asif Ali, a board director Harold Selick, and insider Arturo Molina) sold shares on March 26 — approximately 63,765 shares disclosed across filings, representing several million dollars of stock sold. Large, clustered insider sales are being read negatively by the market and likely contributed to near‑term selling pressure. Insider SEC Filing

Analyst Ratings Changes

A number of equities research analysts have commented on PTGX shares. Barclays upped their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. The Goldman Sachs Group lifted their price objective on Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 3rd. TD Cowen upped their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Citizens Jmp increased their target price on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Finally, Truist Financial raised their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Protagonist Therapeutics has an average rating of “Moderate Buy” and an average target price of $107.31.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.